NEW YORK, NY / ACCESSWIRE / September 23, 2015 / Vascular Biogenics Ltd., (NASDAQ: VBLT) a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, recently announced that complete Phase 2 data on VB-111 in combination with Bevacizumab (Avastin) will be presented at the European Society for Medical Oncology’s (ESMO) European Cancer Congress 2015, being held September 25th-29th in Vienna, Austria.
VB-111 is a novel, intravenously-administered, next generation targeted anti-angiogenic agent that utilizes VBL’s proprietary Vascular Targeting System (VTS) to target endothelial cells in the tumor vasculature for cancer therapy. VB-111 contains a non-replicating adenovirus, a proprietary modified murine pre-proendothelin promoter (PPE-1-3x) and a Fas-Chimera transgene to angiogenic tumor blood vessels, leading to their apoptosis. VB-111 is the first agent based on transcriptional targeting of tumor endothelium to be assessed in a clinical trial. VB-111 completed a Phase 1/2 “all-comers” clinical trial, which demonstrated multiple cases of objective tumor response and disease control and excellent safety and tolerability. VB-111 has Fast Track Designation for recurrent glioblastoma in the US and organ drug status for glioblastoma in both the US and EU. Beyond GBM, VBL is also conducting early phase II studies in thyroid and ovarian cancer.
A company with a drug that appears to work in three separate types of cancers is generally valued much higher than Vascular Biogenics. Either this company has simply gone under the radar or there are underlying issues keeping the market cap well below analyst expectations.
For a more detailed research report with analyst comments and recommendation on Vascular Biogenics Ltd., please follow the link. There is no cost obligation required to view analyst report.
http://bit.ly/-VBLT_Due-Diligence_Report
Copy and paste may be required.
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics’ pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA.
About Broad Street Alerts
We make the connection between sophisticated investors and high quality micro and small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
Safe Harbor Statement
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management’s own knowledge and assessment of the Company’s industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements
Compliance Procedure
Content is researched, written and reviewed on a best-effort basis by a 3rd party analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below.
Contact:
SOURCE: Broad Street Alerts
ReleaseID: 432155
